For biopharma and medtech companies, the decision to go public is predicated on many business decisions—what kind of capital can be raised? Is our investor base strong and interested? Is now the right time? The Nordic Markets offer some distinct advantages at the earlier stage, and also offer new possibilities for US companies to list abroad. And although the specific logistical and mechanical aspects are exceedingly important, at the end of the day, the decision to do something like this is predicated on an amalgam of strategic decisions. In this episode Back Bay Life Science Advisors and Nasdaq outline best practices for companies considering a public listing, including:
Steps in best practice strategy in an increasingly complex market
Advantages of listing with a smaller listing threshold market
Similarities and differences between Nasdaq US and Nasdaq Nordic markets
The strategic change and new dual listing option for US companies
The unique way retail participation makes up a large portion of the Nasdaq Nordic market (>25% of trades come in from retail)
Differences in support for emerging companies, Nordic v. US markets
Jonathan Gertler is CEO of Back Bay Life Science Advisors and Managing Partner at Bioventures Medtech Funds. Maria Groschopp Dellwik is Nasdaq’s Head of Strategy and Business Development for Global Listing Services in the Nordics, where she manages new offerings and key strategic change initiatives to improve listing offerings and the Swedish capital market.Download “Preparing for a Public Listing: Best Practices for Biopharma, Medtech andHealthtech Companies” from Back Bay Life Science Advisors and Nasdaqhttps://bblsa.com/investment-banking-1